Dianalitics
Arqit Quantum Inc.
ARQQ · v1 · 2026-09-15
hourglass
Loading…
Preparing the latest DD data, styles and content.
26RiskyDD: Sep 15, 2026Analyst: 40
paidPrice at analysis date
USD 16.3 (15/09/2026)
domainMkt cap
$270M
pie_chartShares
16.58M
candlestick_chart52W
$11.52-$62.00
trending_downShort interest
6.80%
HIGHNASDAQInformation Technology87 employeesFounded 2017
Verdict: Unfavorable

Pre-revenue-scale quantum encryption narrative name trading at ~250× TTM revenue after a −74% decline from 52W high and a −18.75% single-day drop on 2026-09-14 on insider selling pressure. Cash floor ~$2/share, imminent 5.44M share dilution, ~1 year cash runway. Commercial traction improving (11 contracts H1 FY26 vs 7 in full FY25) but revenue is still <$1.5M annualized against $30M+ annual burn. Base FV $6.5/share = −60% vs $16.29 spot.

📊 DIANALITICS RESEARCH INDEX Company & Thesis Assessment Score /100 — updated 2026-09-15
40
Arqit Quantum Inc. (ARQQ)
Software – Infrastructure · Quantum-safe encryption · NASDAQ · London (UK)
"Real quantum-threat narrative, real technology, real customers — but revenue scale is tiny vs valuation, and dilution is the base-rate outcome."
P/S TTM 248× Cash runway ~12m Dilution 25% YoY Beta 2.28 Rev +307% YoY Oracle Defense
Fin. strength
5
/20 pts
EBITDA/FCF
2
/15 pts
Debt/leverage
10
/15 pts
Stage/business
5
/15 pts
Catalysts
5
/10 pts
Reg. risk
5
/8 pts
Risk/reward
2
/7 pts
Management
2
/5 pts
Sector/macro
3
/3 pts
Compliance
1
/2 pts
💡 Fair Value estimate — Cash floor + probability-weighted commercialization option NPV
Fair value base case
USD 6.50
Range: USD 2.00-USD 22.0
Price at analysis date: USD 16.3 (15/09/2026)
Base upside/downside: -60%

Cash-anchored FV construction is the appropriate frame for a pre-revenue-scale narrative name. Base multiple implied on FY29E revenue = ~18× P/S (still generous). Cross-check hard cash floor: $2.30/share pre-dilution, $1.60/share post-dilution — the current $16.29 print embeds >85% probability of full commercial success plus strategic exit premium, which is not supported by 11 contracts / $623K H1 revenue. Sensitivity: doubling the commercialization probability (30% vs 15%) lifts FV to ~$9 — still 45% below spot. The gap between price and fundamentals-anchored FV is the option premium the market pays for "PQC theme exposure". ⚠️ Not investment advice.

ComponentAssumptionUSD/share
Cash on balance sheetEst. $35M cash + $18M H1 ATM raise − $15M H2 burn ≈ $38M ÷ 16.58M sh+2.30
Post-dilution adjustmentImminent 5.44M new shares × $16 avg placement price ÷ 22.02M post-dilution → net floor $87M ÷ 22M+3.95
Commercialization option (bull path)15% probability × $50M FY29E revenue × 8× P/S = $400M / 22M sh × 15%+2.72
Partnership / IP strategic valueOracle Defense + Sparkle + aerospace partner: 10% probability × $80M strategic acquisition value ÷ 22M+0.36
Cash burn to FY28 breakeven2 years × $25M average burn (declining) = $50M ÷ 22M sh (already partly funded by dilution above)−2.27
Legal / class-action tailClass action settled ($7M paid); residual reserve for insurance recovery timing / any new claim−0.55
FV base caseSum: 2.30 + 3.95 + 2.72 + 0.36 − 2.27 − 0.55≈ $6.5
Bull
$22
Probability: 15%
SKA-Platform gains enterprise adoption through Oracle Defense channel; FY27 revenue $8M+ (10× jump); NIST PQC deadlines force telecom/gov procurement; strategic acquisition premium (Cisco/Palo Alto Networks) at ~10× P/S FY28E.
Base
$6.5
Probability: 45%
Revenue $2–4M FY27, $8–15M FY29; further dilution (5.44M imminent + rolling ATM) offsets partnership progress; multiple compresses toward realistic SaaS levels as narrative fatigue sets in; cash floor + option value converges to $6.5.
Bear
$2
Probability: 40%
Revenue growth stalls below $2M FY27; second dilution round needed at depressed prices; going-concern / Nasdaq listing risk (min. bid price $1); price collapses toward tangible cash floor $2/share; potential 4:1 reverse split to preserve listing.
Methodology: Cash-anchored FV construction is the appropriate frame for a pre-revenue-scale narrative name. Base multiple implied on FY29E revenue = ~18× P/S (still generous). Cross-check hard cash floor: $2.30/share pre-dilution, $1.60/share post-dilution — the current $16.29 print embeds >85% probability of full commercial success plus strategic exit premium, which is not supported by 11 contracts / $623K H1 revenue. Sensitivity: doubling the commercialization probability (30% vs 15%) lifts FV to ~$9 — still 45% below spot. The gap between price and fundamentals-anchored FV is the option premium the market pays for "PQC theme exposure". ⚠️ Not investment advice. Not investment advice.
warning
🚨 Multiple concurrent red flags — read before continuing
1) Cash runway ~12 months at current burn (~$30M/year) without additional raises; 2) imminent 5.44M share dilution (~33% of current 16.58M share count) via F-3 shelf active since Jan 2026, plus prior warrant expiry; 3) −74% decline from 52W high ($62.00 → $16.29) with elevated beta 2.28; 4) $7M securities class action settled June 2026 after Motion to Dismiss was denied — legacy allegations about overstating tech maturity and misrepresenting British government as customer; 5) revenue TTM only $1.09M vs market cap $270M = P/S ~248×.
⚠️ Methodology note: ARQQ is a classic "early-stage narrative" profile per the DD framework (pre-revenue-scale, cash-anchored valuation, high option-value component). Fair value is built as cash floor per share + probability-weighted commercialization option NPV, not as a DCF or peer P/E multiple. The current market price is a narrative multiple on the post-quantum cryptography (PQC) TAM and cannot be reconciled with any fundamental method without heroic assumptions about 2028-2030 revenue scaling.
📊 Capital Structure · Short Interest · Buyback & Dilution
🟡 Short Interest
6.80%
1.06M shares shorted on 16.58M outstanding (Nasdaq official data). Moderate SI; borrow rates elevated. Short thesis: dilution + valuation. Squeeze risk limited given warrant expiry removed the usual gamma catalyst.
🔴 Share dilution (1Y)
+25%
Shares quadrupled since SPAC merger (2021). H1 FY26 alone: $18M raised via ATM equity program. F-3 shelf active since Jan 2026 authorizes further issuance. Imminent 5.44M share addition (~33% of current base).
🔴 Buyback
$0
No buyback and none feasible given cash constraints. All capital allocation directed to R&D + sales/marketing to convert PQC narrative into contracts. Priority remains extending runway via equity raises.
Short Interest — context
ARQQ — 6.80%
6.80%

Short interest at 6.80% is moderate (5–15% band). The Sep 14 −18.75% drop is attributed to an insider selling wave amid a broader tech risk-off session; on Sep 3 the ARQQW warrants expired and were delisted, removing a technical overhang but also a source of derivative activity. Insider Form 4 monitoring recommended: no material open-market buying identified in last 12 months. Class II directors Calabria & Leaver reelected 2026-09-09 AGM with 98.1% approval — governance basic hygiene intact.

$Financial analysis — FY2026 (fiscal year ends Sep 30)
Market cap
$270M
−27.9% MoM
Revenue TTM
$1.09M
+306.7% YoY (from tiny base)
Net loss TTM
−$49M
EPS −$3.12
P/S TTM
248×
Narrative multiple
ItemFY23FY24FY25FY26EGuidance FY26 / FY27E
Revenue ($M)0.090.290.53~1.22.5–4.0 (FY27E)
Number of contracts35715+20–30 (FY27E)
Operating loss ($M)−54.1−48.3−35.3−32.0−25.0 (FY27E)
Cash burn ($M)−45−38−30−28−22 (FY27E)
Cash & equivalents ($M)~90~55~35~40 (post-ATM)~30 (post-dilution)
Shares outstanding (M)4.17.513.216.5822.0+ (post-dilution)
Revenue trajectory is genuinely accelerating (from tiny base), but the absolute scale is orders of magnitude below the market cap implied. Losses narrowing but still consume ~25× annual revenue. FY26E figures reflect H1 actuals + H2 estimate; FY27E is midpoint of independent estimates.
Half-year dynamics — recent periods (fiscal year Oct–Sep)
MetricH1 FY24H2 FY24H1 FY25H2 FY25H1 FY26
Revenue ($K)11018367463623
Contracts (active)344711
Op. loss ($M)−26.5−21.8−19.2−16.1−15.5
End-of-period cash ($M)6855423540
Shares (M, end period)6.57.510.813.216.58
Financial position and sustainability
Cash runway (months at current burn)
~12 mo
Gross margin (H1 FY26)
~70%
Revenue / market cap ratio
0.4%
Debt / equity (senior debt)
~0
account_tree

Business model — Quantum-safe encryption & PQC migration platform

Symmetric-key quantum-safe encryption via SaaS + on-premise appliance
Arqit's core product is SKA-Platform (Symmetric Key Agreement) — cryptographic key generation that is claimed to be quantum-resistant. Distributed via QuantumCloud (PaaS) and integrated with partner networks (telecom, government, defense). Additional products: Encryption Intelligence (automated cryptographic discovery for PQC migration compliance, launched Jan 2026) and SKA Central Controller (Nov 2025) for managed service providers. Business model: recurring SaaS licenses + integration services. Target markets: telecom operators, government/defense, financial services. Revenue trajectory FY25 → FY26E: 7 → 15+ contracts, $0.53M → ~$1.2M — real progress but absolute scale still very small vs $270M market cap.

SKA-Platform + QuantumCloud ~70% of revenue FY26E 🟢 ramping Core PaaS: symmetric key delivery for quantum-safe VPNs, network encryption. Anchor partnerships: Sparkle (Italian Tier-1 telecom, 20 Equinix DCs), Oracle Defense Ecosystem (2026), Es'hailSat satellite (Sep 2026 demo). Bill model: annual license + usage. Encryption Intelligence (EI) ~15% of revenue FY26E 🟡 early commercial Automated cryptographic discovery / PQC migration compliance tool (launched Jan 2026). Larger TAM than SKA (every enterprise needs cryptographic inventory before PQC migration deadlines). Higher-margin, but competitive vs incumbents (Palo Alto, ISARA, PQShield). Services + government projects ~15% of revenue FY26E 🟡 bid activity Bespoke integration services for government/defense customers. 8 government/defense/enterprise contracts in H1 FY26. Aerospace & defense partner (likely UK primes) renewed & upsized ~90% in May 2026. Lumpy, low-visibility revenue.

gavel

Legal, regulatory and risk analysis

Dilution risk (near-term structural)
Critical
Imminent 5.44M share dilution (~33% of current 16.58M float) is base-rate outcome given F-3 shelf active since Jan 2026 and ATM raises in progress. Share count has quadrupled since SPAC (2021). Every extra $10M raised at $15/share adds ~4% dilution.
Cash runway ~12 months
Critical
$30M/year burn against $35–40M cash (post H1 ATM). Even with reduced FY27 burn (~$22M) the company will need another equity raise within 12 months barring a step-change in revenue. Debt financing not available at meaningful scale for a going concern.
Valuation vs fundamentals gap
High
P/S TTM 248× is unsupportable via traditional methods. Requires 20–30× revenue growth by FY29 just to reach a fair 15× P/S peer multiple. Narrative fatigue events (missed contract, delayed rollout) can collapse the multiple 30–60% in weeks.
Nasdaq listing / min-bid risk
Moderate
Currently at $16.29, well above Nasdaq $1 minimum bid. But in bear scenario ($2 FV) a reverse stock split becomes likely. Arqit has done reverse splits historically (post-SPAC). Reverse split is a signal of distress but not a solvency issue by itself.
Legacy class action resolved
Low
$7M securities class action fully settled June 2026 (SDNY approved). Allegations of overstating tech maturity + misrepresenting British gov "customer" are behind the company. Motion to Dismiss was denied March 2025 (material fact — settlement pre-empted trial). No SEC investigation active.
Technology thesis is real (positive)
Positive
PQC migration is a real regulatory driver: NIST finalized PQC standards in 2024; NSA/CNSA 2.0 mandates PQC for national security systems by 2033; UK NCSC has similar guidance. Sector tailwind is genuine and multi-year — creating a floor on strategic value.
Partnership momentum
Positive
Oracle Defense Ecosystem (2026), Sparkle (Tier-1 telecom), Es'hailSat/AIEE satellite (Sep 2026), nLighten (Jul 2026), Tomorrow Street/Vodafone JV, 6WIND, RAD — genuine multi-vendor traction. Aerospace partner upsized contract 90% (May 2026) is the strongest single-customer datapoint.
Competitive intensity
High
PQC migration is a rich competitive field: PQShield, ISARA, SandboxAQ, IBM/Quantinuum, Palo Alto Networks (recent PQC pivot), Thales, Cisco. Arqit's IP position (symmetric key agreement) is differentiated but not moated — customers may prefer standards-based NIST algorithms over Arqit's proprietary approach.
article

SWOT analysis

Strengths
  • +Real, differentiated technology (SKA-Platform) with satellite + terrestrial deployment history
  • +Genuine commercial momentum: 11 contracts H1 FY26 vs 7 total FY25 (+57% contract count)
  • +Blue-chip partnership roster (Oracle, Sparkle, aerospace & defense primes)
  • +Class action legacy fully resolved (June 2026 SDNY settlement approved)
Weaknesses
  • Revenue TTM $1.09M vs mkt cap $270M — valuation completely detached from fundamentals
  • Cash burn $30M+/year vs $35–40M cash = ~12 month runway
  • History of dilution (share count 4× since SPAC), imminent +33% dilution pending
  • Governance credibility damaged by pre-2024 disclosures (settled but publicly documented)
Opportunities
  • NIST/NSA PQC deadlines (2033 CNSA 2.0) force massive gov/defense migration cycle
  • Encryption Intelligence tool addresses the discovery-first phase (broader TAM than SKA alone)
  • Strategic acquisition target: Cisco/Palo Alto/Thales could see value in IP + gov relationships
  • Satellite & edge quantum-safe use cases (Es'hailSat demo Sept 2026, nLighten edge)
Threats
  • !NIST-standardized PQC algorithms may prevail over Arqit's proprietary SKA approach
  • !Large cybersecurity vendors (Palo Alto, Cisco) bundling PQC free with existing platforms
  • !Insider selling waves (Sep 14 −19% drop) undermine share price stability
  • !Prolonged risk-off in quantum narrative cohort (IONQ, RGTI, QBTS beta correlation)
article

Summary by assessment area

🎯 Investment thesis — Unfavorable
  • Real technology + real customer traction, but revenue scale (~$1M) 250× below market cap
  • Cash-anchored FV $6.5 = −60% vs spot $16.29; current price prices in >85% commercialization success probability
  • Bear case $2 (cash floor post-dilution) is the more probable outcome (40%) vs bull case $22 (15%)
  • Not a "value" setup, not a "quality" setup — pure narrative long-duration option
⚠️ Key risks — Critical
  • Imminent 5.44M share dilution (+33%) via active F-3 shelf
  • ~12 month cash runway forces further equity raises at potentially depressed prices
  • Insider selling pressure (Sep 14 drop) + high beta 2.28 = amplified downside in any risk-off
  • Competitive threat from NIST-standardized PQC vs Arqit's proprietary approach
🔑 Catalysts to watch — Moderate
  • FY26 full-year results (Dec 2026): revenue actual vs $1.2M contracted, cash balance disclosure
  • Any strategic contract announcement >$5M (Oracle Defense channel, gov/defense primes)
  • F-3 shelf drawdown announcement (dilution event) — negative catalyst
  • NIST PQC procurement milestones from gov/defense agencies (2027)
Sources & Disclaimer

Sources: StockAnalysis.com (ARQQ overview, price history, statistics — accessed 2026-09-15); Arqit Quantum Inc. Form 6-K H1 FY2026 results (2026-05-21, GlobeNewswire); Arqit Quantum FY2025 annual results (2025-12-09); Arqit F-3 shelf registration (2026-01-23, SEC); TipRanks — $7M class action settlement (2026-01-09, approved 2026-06-01); Arqit AGM transcript (2026-09-09); Nasdaq official short interest data (1.06M shares / 6.80%); Kalkine — Arqit −19% on insider selling wave (2026-09-14); GlobeNewswire — Arqit + Es'hailSat + AIEE quantum-safe satellite demo (2026-09-01); Oracle Defense Ecosystem announcement (2026); Sparkle partnership (2025-12-03). Market data — last verified close 2026-09-14 ($16.29): ARQQ ~$16.29, market cap ~$270M, 52W: $11.52–$62.00, shares outstanding 16.58M. Short interest 6.80%. Est. cash balance $38–40M (post H1 ATM). Beta 2.28. No sell-side analyst coverage. This document is for informational purposes only and does not constitute financial or investment advice.